INFO:

Representatives from Pfizer and Curevac share their views on past and present manufacturing, distribution and equitable access of the COVID-19 vaccines and therapeutics. The debate focuses on the activities undertaken to develop vaccines for new variants, the authorisation process, and transparency of contracts. Extracts from the exchange of views with Janine Small, President of International Developed Markets, Pfizer and and Dr Franz-Werner Haas, Chief Executive Officer, Curevac.